{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:08:42Z","timestamp":1770818922086,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.11.031","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:59:17Z","timestamp":1264499957000},"page":"2290-2311","source":"Crossref","is-referenced-by-count":41,"special_numbering":"P2","title":["Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Trevor W.","family":"Dennie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.031_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.clinthera.2009.11.031_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.11.031_bib4","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [published correction appears in Blood. 2008;112:5259]","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.031_bib5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/sj.leu.2403154","article-title":"Unsolved issues in CLL biology and management","volume":"17","author":"Dighiero","year":"2003","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.031_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.031_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2009.11.031_bib8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.leu.2403707","article-title":"Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia","volume":"19","author":"Schroers","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.clinthera.2009.11.031_bib9","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.11.031_bib10","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2005-02-0819","article-title":"How I treat refractory CLL","volume":"107","author":"Montserrat","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2009.11.031_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1749-6632.1958.tb42649.x","article-title":"Clinical evaluation of CB 1348 in malignant lymphoma and related diseases","volume":"68","author":"Israels","year":"1958","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.clinthera.2009.11.031_bib12","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2107::AID-CNCR7>3.0.CO;2-L","article-title":"High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial","volume":"79","author":"Jaksic","year":"1997","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2009.11.031_bib13","first-page":"433","article-title":"CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): Preliminary results of a randomized multicenter study","volume":"30","author":"Hansen","year":"1988","journal-title":"Nouv Rev Fr Hematol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.clinthera.2009.11.031_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.seminhematol.2004.05.004","article-title":"Advances in chemotherapy for chronic lymphocytic leukemia","volume":"41","author":"Wendtner","year":"2004","journal-title":"Semin Hematol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.clinthera.2009.11.031_bib17","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1055\/s-0028-1110470","article-title":"Treatment of multiple myeloma with a new cytostatic agent: Gamma-lmethyl- 5-bis-(beta-chlorethyl)-aminobenzimidazolyl-( 2)-butyric acid hydrochloride [in German]","volume":"94","author":"Anger","year":"1969","journal-title":"Dtsch Med Wochenschr."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.11.031_bib18","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3816\/CLM.2007.s.028","article-title":"Bendamustine in non-Hodgkin lymphoma: The double-agent that came from the Cold War","volume":"8","author":"Forero-Torres","year":"2007","journal-title":"Clin Lymphoma Myeloma."},{"key":"10.1016\/j.clinthera.2009.11.031_bib20","article-title":"Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study","volume":"110","author":"Knauf","year":"2007"},{"key":"10.1016\/j.clinthera.2009.11.031_bib21","article-title":"Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: An updated analysis from an international phase III study","volume":"112","author":"Knauf","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.031_bib22","article-title":"Bendamustine is safe and effective in patients with rituximabrefractory, indolent B-Cell non-Hodgkin lymphoma","volume":"110","author":"Kahl","year":"2007"},{"issue":"Suppl 13","key":"10.1016\/j.clinthera.2009.11.031_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib25","first-page":"458","article-title":"Pharmacokinetics of bendamustine in patients with malignant tumors","volume":"14","author":"Matthias","year":"1995","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib26","first-page":"782","article-title":"The pharmacokinetics of bendamustine (Cytostasane) in humans [in German]","volume":"40","author":"Preiss","year":"1985","journal-title":"Pharmazie."},{"key":"10.1016\/j.clinthera.2009.11.031_bib27","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","article-title":"A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours","volume":"96","author":"Rasschaert","year":"2007","journal-title":"Br J Cancer."},{"key":"10.1016\/j.clinthera.2009.11.031_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CAD.0b013e3280149eb1","article-title":"A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors","volume":"18","author":"Rasschaert","year":"2007","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.clinthera.2009.11.031_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0331-5","article-title":"Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride","volume":"59","author":"Teichert","year":"2007","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib30","first-page":"564","article-title":"Influence of hepatic and renal function on the pharmacokinetics of bendamustine","volume":"41","author":"Teichert","year":"2003","journal-title":"Intl J Clin Pharm Ther."},{"key":"10.1016\/j.clinthera.2009.11.031_bib31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/dmd.105.003624","article-title":"Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma","volume":"33","author":"Teichert","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.clinthera.2009.11.031_bib32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/CAD.0b013e32803d36e6","article-title":"A pilot study of bendamustine in advanced bile duct cancer","volume":"18","author":"Schoppmeyer","year":"2007","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.clinthera.2009.11.031_bib33","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica."},{"key":"10.1016\/j.clinthera.2009.11.031_bib34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study [published correction appears in J Clin Oncol. 2008;26:1911]","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol."},{"issue":"Suppl 13","key":"10.1016\/j.clinthera.2009.11.031_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/sonc.2002.34876","article-title":"Bendamustine in the treatment of multiple myeloma: Results and future perspectives","volume":"29","author":"P\u00f6nisch","year":"2002","journal-title":"Semin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.031_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.clinthera.2009.11.031_bib37","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow","year":"2001","journal-title":"Haematologica."},{"key":"10.1016\/j.clinthera.2009.11.031_bib38","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/Mitoxantrone\/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.031_bib39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High antilymphoma activity of bendamustine\/ mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.clinthera.2009.11.031_bib40","first-page":"33","article-title":"Anti-CD20 antibody (IDECC2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica."},{"key":"10.1016\/j.clinthera.2009.11.031_bib41","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In vitro evaluation of bendamustine induced apoptosis in Bchronic lymphocytic leukemia","volume":"16","author":"Schw\u00e4nen","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2009.11.031_bib42","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V110.11.3122.3122","article-title":"The purine nucleoside phosphorylase inhibitor forodesine (BCX-1777) is a potent cytotoxic agent and has synergistic activity with bendamustine in chronic lymphocytic leukemia (CLL) irrespective of ZAP-70 levels and p53 status","volume":"110","author":"Alonso","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2009.11.031_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-008-0453-8","article-title":"Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro","volume":"135","author":"Schmidt-Hieber","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/PL00008463","article-title":"Repeated administration of short infusions of bendamustine: A phase I study in patients with advanced progressive solid tumours","volume":"126","author":"Sch\u00f6ffski","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","article-title":"Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours","volume":"11","author":"Sch\u00f6ffski","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib46","article-title":"Recurrent ENT tumors treated with bendamustine or gemcitabine and radiotherapy","volume":"19","author":"Schilcher","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/PL00002397","article-title":"Palliative radiochemotherapy with Bendamustin for advanced recurrent head and neck tumors [in German]","volume":"177","author":"Rahn","year":"2001","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00066-007-1597-1","article-title":"Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck","volume":"183","author":"Bottke","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00044011-200424100-00007","article-title":"Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC)","volume":"24","author":"K\u00f6ster","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2009.11.031_bib50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00280-008-0821-8","article-title":"Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial","volume":"63","author":"Loibl","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1042819031000123546","article-title":"Bendamustine plus mitoxantrone\u2014a new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I\/II study","volume":"45","author":"K\u00f6ppler","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2009.11.031_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","article-title":"Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pretreated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy","volume":"132","author":"Lissitchkov","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib53","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma\u2014a multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","author":"Koenigsmann","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2009.11.031_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2008.07076.x","article-title":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a Phase I clinical trial","volume":"143","author":"P\u00f6nisch","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib55","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","article-title":"Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas","volume":"12","author":"Heider","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2009.11.031_bib56","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade non-Hodgkin'slymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib58","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib59","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.11.031_bib60","article-title":"Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients","volume":"26","author":"Rummel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib62","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-linetreatment of patients with follicular, indolent and mantle cell lymphomas: Results of a randomized phase III study","volume":"112","author":"Rummel","year":"2008"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2009.11.031_bib63","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/jco.2007.25.18_suppl.8034","article-title":"Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Longterm follow-up of a phase II study","volume":"25","author":"Rummel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 13","key":"10.1016\/j.clinthera.2009.11.031_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2002.34875","article-title":"Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives","volume":"29","author":"Aivado","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib66","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial","volume":"112","author":"Fischer","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.031_bib67","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2009.11.031_bib68","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1080\/10428190701694194","article-title":"Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma","volume":"48","author":"Fenk","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2009.11.031_bib69","article-title":"Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: A single-center Phase I\/II study","volume":"112","author":"Moosmann","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.031_bib70","article-title":"Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory\/relapsed multiple myeloma","volume":"110","author":"Poenisch","year":"2007"},{"key":"10.1016\/j.clinthera.2009.11.031_bib71","first-page":"124","article-title":"Bendamustine versus melphalan in the primary treatment of multiple myeloma. A randomized prospective study","author":"Blumenstengel","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"P\u00f6nisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib73","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","article-title":"Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC","volume":"16","author":"von Minckwitz","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2009.11.031_bib74","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.JTO.0000263714.46449.4c","article-title":"Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer","volume":"2","author":"K\u00f6ster","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinthera.2009.11.031_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.09.029","article-title":"Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients","volume":"55","author":"Schmittel","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2009.11.031_bib76","first-page":"570","article-title":"Chemotherapy of advanced nonsmall-cell and small-cell bronchial carcinoma with bendamustine\u2014a phase II study [in German]","volume":"52","author":"Reck","year":"1998","journal-title":"Pneumologie"},{"key":"10.1016\/j.clinthera.2009.11.031_bib77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00008390-200412000-00001","article-title":"A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma","volume":"14","author":"Schmidt-Hieber","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clinthera.2009.11.031_bib78_1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/cncr.22846","article-title":"Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study","volume":"15","author":"Hartmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.031_bib78_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/cncr.22846","article-title":"Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study","volume":"110","author":"Hartmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.031_bib79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00001813-200008000-00003","article-title":"Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2009.11.031_bib80","series-title":"Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins","author":"Cozza","year":"2003"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T01:23:33Z","timestamp":1590542613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":78,"alternative-id":["S0149291809004317"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.031","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}